Upstream Bio, Inc. (UPB) stock
Close on Nov 11, 2026Market cap $175.27MP/E –Yield –
Upstream Bio, Inc. grew revenue 2.5% to $2.87M over the twelve months to Sep 30, 2026. Free cash flow was -$133.44M. At the latest close the market valued the company at $175.27M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $175.27M
- P/E ratio
- –
- Price to sales
- 61.07
- Price to book
- 0.75
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $2.87M
- Net income
- -$163.94M
- EPS, diluted
- -$3.01
- Free cash flow
- -$133.44M
- Book value per share
- $4.27
- Diluted shares
- 55M
Trading
- Next earnings
- Mar 25, 2027 (estimated, before the open)
- Previous close
- $3.38
- Open
- $3.38
- Day's range
- $3.13 – $3.46
- Volume
- 1,318,902
- Average volume (20 days)
- 1,288,535
- Index membership
- Russell 2000 (since Dec 2024), Russell 3000 (since Nov 2024)
- Beta (5 years)
- 1.35
- 52-week range
- $2.68 – $33.68
- RSI (14 days)
- 41.4
- Volatility (1 year)
- 92.3%
- Relative volume
- 1.64×
- WACC
- 11.6%
On 2 of our idea lists: Net-nets, More cash than they're worth
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | UPB | S&P 500 | Difference | UPB per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -31.9% | -2.4% | −29.5 pts | ||
| 3 months | -54.9% | -1.2% | −53.7 pts | ||
| Year to date | -88.2% | +12.3% | −100.5 pts | ||
| 1 year | -86.5% | +12.4% | −99.0 pts |
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Upstream Bio filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Results
- Results
- Results
About Upstream Bio
Pharmaceutical Preparations
The company is a clinical-stage biotechnology company that focuses on developing treatments for severe inflammatory and respiratory disorders. Its primary investigational drug candidate is verekitug, a recombinant human monoclonal antibody designed to bind and inhibit the Thymic Stromal Lymphopoietin receptor. The company is advancing this product candidate across clinical programs for indications such as severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Its target patient population consists of individuals suffering from severe immune-mediated conditions underserved by current standards of care.
Company profile, executives and historyUpstream Bio stock: common questions
What is Upstream Bio's stock price?
UPB closed at $3.20 on Nov 11, 2026, down 5.33% on the day. Over the past 52 weeks it traded between $2.68 and $33.68.
What is Upstream Bio's market cap?
Upstream Bio was worth $175.27M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is UPB's P/E ratio?
Upstream Bio lost money over the twelve months to Sep 30, 2026 (diluted EPS -$3.01), so it has no meaningful P/E ratio.
How much revenue does Upstream Bio make?
Upstream Bio reported revenue of $2.87M for the twelve months to Sep 30, 2026, up 2.5% from a year earlier.
Does Upstream Bio pay a dividend?
No. Upstream Bio has not paid a cash dividend over the last twelve months.
When does Upstream Bio report earnings next?
Upstream Bio is expected to report Q4 FY2026 results on Mar 25, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has UPB stock performed over the past year?
Including dividends, UPB returned -86.5% over the past year, against +12.4% for the S&P 500.
How many UPB shares are sold short?
4M shares were sold short at the latest FINRA report, 7.09% of the float, or 2.7 days of average trading volume.
Who are Upstream Bio's competitors?
Companies most similar to Upstream Bio by business, industry and size include CNTB, DNTH, ACRS, VTGN, MCRB.
See a number that looks wrong?